Neutralizing antibody titres to SARS-CoV-2 Omicron variant and wild-type virus in those with past infection or vaccinated or boosted with mRNA BNT162b2 or inactivated CoronaVac vaccines

Omicron, a novel SARS-CoV-2 variant has emerged and is rapidly becoming the dominant SARS-CoV-2 virus circulating globally. It is important to define reductions in virus neutralizing activity in serum of convalescent or vaccinated individuals to understand potential loss of protection from infection...

Descripción completa

Detalles Bibliográficos
Autores principales: Peiris, Malik, Cheng, Samuel, Mok, Chris Ka Pun, Leung, Yonna, Ng, Susanna, Chan, Karl, Ko, Fanny, Yiu, Karen, Lam, Bosco, Lau, Eric, Chan, Ken, Luk, Leo, Li, John, Tsang, Leo, Poon, Leo, Chen, Chunke, Hui, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750710/
https://www.ncbi.nlm.nih.gov/pubmed/35018372
http://dx.doi.org/10.21203/rs.3.rs-1207071/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750710/
https://www.ncbi.nlm.nih.gov/pubmed/35018372
http://dx.doi.org/10.21203/rs.3.rs-1207071/v1

Ejemplares similares